ArticleCurrent genomics2025
YY2 Serves as a Novel Prognostic Biomarker Correlated with Immune Microenvironment and Glycolysis in Esophageal Carcinoma.
Article in Current genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- LMNTD2-AS1 promotes esophageal squamous cell carcinoma progression by sponging miR-449b-5p to upregulate MYCN.World journal of surgical oncology · 2026Article
- Discovery and validation of a prognostic SPP1/PLAU signature in HPV-negative oropharyngeal squamous cell carcinoma.BMC medical genomics · 2026Article
- LncRNA AFAP1-AS1 mediates therapy-dependent expression of CCL5, CXCL10 and MMP9 in multiple sclerosis.Biochemistry and biophysics reports · 2026Article
- TRIM11 is upregulated in esophageal cancer and promotes tumor progression through modulation of the β-catenin signaling pathway.Functional & integrative genomics · 2026Article
- Emerging roles of Notch signaling in the tumor microenvironment of digestive system cancers.Frontiers in molecular biosciences · 2026Review
- Crosstalk between the microbiome and immune microenvironment in the pathogenesis and treatment of thyroid carcinoma: a narrative review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Yin Yang 2 (YY2) plays a pivotal role in various tumorigenic processes; however, its specific involvement in esophageal carcinoma (ESCA) remains elusive. This study aims to investigate the expression and potential functional significance of YY2 in ESCA. Methods: The expression and functions of YY2 in ESCA were analyzed using a broad range of bioinformatics databases and tools, including TCGA, TIMER, TISIDB, QUANTISEQ, cBioPortal, DNMIVD, LinkedOmics, DAVID, GSEA, GEPIA2, LASSO, miRWalk, miRDB, and TargetScan. Furthermore, RT-qPCR, immunohistochemical staining, western blot, CCK8 assay, and wound healing assay were employed to validate the involvement of YY2 in ESCA pathogenesis. Results: Bioinformatics analyses revealed that the YY2 gene is upregulated in ESCA tissues, with its high expression significantly associated with poor prognosis and elevated levels of M2 macrophages, NK cells, Tregs, CTLA4, TIGIT, and Siglec-15. Validating the ESCA samples demonstrated that knockdown of YY2 effectively inhibited cell proliferation and migration in ESCA cells. The biological functions of YY2 and its co-expressed genes were primarily associated with transcriptional regulation, DNA methylation, glycometabolism, and ubiquitination. Moreover, the regulatory network of YY2 in the glycolysis pathway was found to involve multiple genes and miRNAs. Finally, a prognostic model based on YY2 and its associated glycolysis genes revealed a strong inverse correlation between higher risk scores and lower survival rates in esophageal adenocarcinoma (EAC). Conclusion: YY2 may serve as a promising prognostic biomarker and an innovative therapeutic target for patients with ESCA, regulating cell proliferation, migration, immune microenvironment, and glycolysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.